Boston Scientific Predicts IVT Revenues Will Balloon Following Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific remains committed to ongoing merger negotiations with Medinol despite its $345 mil. cash acquisition of Interventional Technologies, which gives it access to IVT's LP coronary stent line.